PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101, which is an IV formulation of suramin. According to the announcement, this is an important milestone achievement as the company works toward enabling a New Drug Application (“NDA”) submission to the … Continue reading InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101